Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Long non-coding RNAs (lncRNAs) have emerged as critical regulators of CRC progression, yet the role of CTBP1-AS2 remains poorly understood. Materials and Methods: CTBP1-AS2 and miR-93-5p expression were analyzed in CRC tissues and cell lines. Functional assays investigated the impact of CTBP1-AS2 on cell proliferation, invasion, and apoptosis. The mechanistic link between CTBP1-AS2, miR-93-5p, and the TGF-β/SMAD2/3 pathway was explored using bioinformatics and dual-luciferase reporter assays. Results: CTBP1-AS2 was significantly overexpressed in CRC and associated with poor patient survival. Functionally, CTBP1-AS2 promoted proliferation and invasion while inhibiting apoptosis. Mechanistically, CTBP1-AS2 acts as a competitive endogenous RNA (ceRNA) for miR-93-5p, thereby activating the TGF-β/SMAD2/3 signaling pathway. Conclusion: CTBP1-AS2 drives CRC development via the miR-93-5p/TGF-β/SMAD2/3 axis, suggesting its potential as a therapeutic target.
Introduction
Colorectal cancer (CRC) remains one of the most prevalent and lethal malignancies globally. Despite advancements in treatment, the molecular mechanisms driving its aggressive growth and metastasis are not fully understood. Recent research has highlighted the role of long non-coding RNAs (lncRNAs)—transcripts exceeding 200 nucleotides that lack protein-coding potential—as key regulatory "switches" in oncogenesis. This study investigates CTBP1-AS2, an lncRNA previously associated with metabolic disorders, to determine its functional significance and clinical relevance in CRC.
Methods
The study utilized a multi-disciplinary approach combining clinical data, in vitro cell biology, and in vivo animal models:
- Clinical Correlation: CTBP1-AS2 expression was measured in 50 pairs of CRC and adjacent normal tissues using RT-PCR. Public datasets (TCGA via GEPIA) were used for external validation.
- Functional Assays: CRC cell lines (SW620, HT29, etc.) were used for gain-of-function (overexpression) and loss-of-function (siRNA knockdown) experiments to observe changes in proliferation, colony formation, and invasion.
- Mechanistic Verification: The competitive endogenous RNA (ceRNA) hypothesis was tested using Dual-Luciferase Reporter Assays and RNA Immunoprecipitation (RIP) to confirm binding between CTBP1-AS2 and miR-93-5p.
- Animal Models: Nude mouse models were employed to evaluate the effect of CTBP1-AS2 levels on tumor volume and metastasis in a living system.
Results
CTBP1-AS2 Upregulation and Clinical Significance
Analysis of clinical samples revealed that CTBP1-AS2 is significantly overexpressed in CRC tissues compared to adjacent healthy tissues ($p < 0.001$). This finding was corroborated by TCGA data (COAD and READ datasets) and observed across multiple CRC cell lines relative to normal intestinal epithelial cells (FHC). Importantly, high CTBP1-AS2 expression was significantly correlated with reduced overall survival in patients ($p = 0.0321$).
Functional Impact on Tumor Progression
Silencing CTBP1-AS2 significantly inhibited the proliferation and invasive capacity of CRC cells. Conversely, overexpression of CTBP1-AS2 enhanced these malignant traits. Furthermore, knockdown of this lncRNA triggered apoptosis, evidenced by increased levels of pro-apoptotic proteins like Bax and cleaved Caspase-3. In vivo experiments confirmed that reducing CTBP1-AS2 levels led to smaller tumor volumes and a decrease in metastatic nodules in the lungs.
The miR-93-5p/TGF-β/SMAD2/3 Axis
Mechanistically, the study identified miR-93-5p as a direct target of CTBP1-AS2. In CRC, miR-93-5p is typically downregulated and acts as a tumor suppressor by inhibiting the TGF-β pathway. CTBP1-AS2 functions as a molecular "sponge," sequestering miR-93-5p and thereby releasing the inhibition of the TGF-β/SMAD2/3 signaling pathway. This activation drives the aggressive phenotype of CRC cells.
Discussion
The identification of the CTBP1-AS2/miR-93-5p/TGF-β/SMAD2/3 axis provides new insights into the molecular landscape of CRC. CTBP1-AS2 emerges not only as a driver of tumor growth and metastasis but also as a potent prognostic marker. While the TGF-β pathway has complex roles in cancer, this study demonstrates how it is hijacked by lncRNAs to promote advanced-stage progression. Future research should focus on the feasibility of targeting CTBP1-AS2 therapeutically and its potential use in non-invasive diagnostic screenings.
Summary updated